Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb 14;194(6):E218.
doi: 10.1503/cmaj.220081. Epub 2022 Feb 3.

Nirmatrelvir-ritonavir for COVID-19

Emily G McDonald  1 , Todd C Lee  2
Affiliations
Comment

Nirmatrelvir-ritonavir for COVID-19

Emily G McDonald et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Emily McDonald reports receiving salary support from the Fonds de Recherche Santé–Québec, and operating funds from the Canadian Institutes of Health Research (CIHR). Dr. McDonald also holds copyright in the software MedSafer. Todd Lee reports receiving research salary support from the Fonds de Recherche Santé–Québec, and operating funds from CIHR and the Interdisciplinary Initiative in Infection and Immunity (MI4). Dr. Lee also holds copyright in the software MedSafer.

Comment in

Comment on

  • Renalism.
    Hiremath S. Hiremath S. CMAJ. 2022 Aug 2;194(29):E1040. doi: 10.1503/cmaj.146430-l. CMAJ. 2022. PMID: 35918093 Free PMC article. No abstract available.

References

    1. The COVID-19 Treatment Guidelines Panel’s statement on potential drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and concomitant medications. Bethesda (MD): National Institutes of Health; updated 2021 Dec. 30. Available: https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-pa... (accessed 2022 Jan. 16).
    1. Product monograph including patient medication information: Paxlovid. Kirkland (QC): Pfizer Canada ULC; 2022. Available: https://pdf.hres.ca/dpd_pm/00064313.PDF (accessed 2022 Jan. 23).
    1. Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death. New York: Pfizer; 2021. Available: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-an... (accessed 2022 Jan. 17).
    1. Lee TC, Morris AM, Grover SA, et al. . Outpatient therapies for COVID-19: How do we choose? Open Forum Infect Dis 2022. Jan. 19 [Epub ahead of print]. doi: 10.1093/ofid/ofac008. - DOI - PMC - PubMed
    1. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. Silver Spring (MD): US Food and Drug Administration; revised 2021 Dec. 22. Available: https://www.fda.gov/media/155050/download (accessed 2022 Jan. 16).

Publication types